Naiyer A Rizvi

Naiyer A Rizvi

UNVERIFIED PROFILE

Are you Naiyer A Rizvi?   Register this Author

Register author
Naiyer A Rizvi

Naiyer A Rizvi

Publications by authors named "Naiyer A Rizvi"

Are you Naiyer A Rizvi?   Register this Author

75Publications

6452Reads

48Profile Views

Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib.

J Thorac Oncol 2019 Sep 18;14(9):1547-1555. Epub 2019 May 18.

University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.04.028DOI Listing
September 2019

Combining chemotherapy with PD-1 blockade in NSCLC.

Pharmacol Ther 2018 06 31;186:130-137. Epub 2018 Jan 31.

Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New York, NY 10032, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01637258183001
Publisher Site
http://dx.doi.org/10.1016/j.pharmthera.2018.01.003DOI Listing
June 2018

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.

Cancer Cytopathol 2017 Dec 12;125(12):896-907. Epub 2017 Oct 12.

Department of Pathology and Cell Biology, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.21937DOI Listing
December 2017

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11;377(20):1986-1988

From Columbia University Medical Center, New York (N.A.R.); and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (S.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1711430DOI Listing
November 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

The use of immunotherapy in the first-line treatment of lung cancer.

Authors:
Naiyer A Rizvi

Clin Adv Hematol Oncol 2017 Mar;15(3):190-192

Columbia University Medical Center, New York, New York.

View Article

Download full-text PDF

Source
March 2017

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2969-79. Epub 2016 Jun 27.

Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.66.9861
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.66.9861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569693PMC
September 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2980-7. Epub 2016 Jun 27.

Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569692PMC
September 2016

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

J Immunother Cancer 2016 16;4:48. Epub 2016 Aug 16.

NewYork-Presbyterian/Columbia University Medical Center, Hematology/Oncology, 177 Fort Washington Avenue, 6GN-435, New York, NY 10032 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0153-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986262PMC
August 2016

Immunotherapy for Advanced Lung Cancer.

Cancer J 2015 Sep-Oct;21(5):383-91

From the *Division of Hematology/Oncology, Columbia University Medical Center; and †Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000151DOI Listing
June 2016

Into the Clinic With Nivolumab and Pembrolizumab.

Oncologist 2016 05 29;21(5):527-8. Epub 2016 Mar 29.

Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861376PMC
May 2016

Immunotherapy and Oncogenic Pathways: The PTEN Connection.

Cancer Discov 2016 Feb;6(2):128-9

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746001PMC
February 2016

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

Clin Lung Cancer 2015 Nov 20;16(6):514-22. Epub 2015 Apr 20.

Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750397PMC
November 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Science 2015 Apr 12;348(6230):124-8. Epub 2015 Mar 12.

Weill Cornell Medical College, New York, NY, 10065, USA. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aaa1348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154PMC
April 2015

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

J Pharm Biomed Anal 2014 Nov 12;100:199-204. Epub 2014 Aug 12.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085140037
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179924PMC
November 2014

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

J Thorac Oncol 2014 Oct;9(10):e73-4

*Thoracic Oncology Service, Department of Medicine; †Computational Biology Center; ‡Thoracic Service, Department of Surgery; §Department of Pathology, Memorial Sloan-Kettering Cancer Center; and ‖Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153071
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655969PMC
October 2014

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Cancer Chemother Pharmacol 2013 Aug 28;72(2):453-61. Epub 2013 Jun 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2219-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653739PMC
August 2013

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

J Thorac Oncol 2012 May;7(5):856-65

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31824c943fDOI Listing
May 2012

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.

Cancer Chemother Pharmacol 2011 Nov 3;68(5):1331-7. Epub 2011 Apr 3.

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1621-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581346PMC
November 2011

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

J Thorac Oncol 2011 Aug;6(8):1435-7

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318223c099DOI Listing
August 2011

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Clin Cancer Res 2011 Apr 19;17(8):2521-7. Epub 2011 Jan 19.

Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2662DOI Listing
April 2011

A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.

J Thorac Oncol 2011 Mar;6(3):624-6

Division of Solid Tumor Oncology, Thoracic Oncology Services, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641532221
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e318207f788DOI Listing
March 2011

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Cancer Chemother Pharmacol 2010 Nov 18;66(6):1079-85. Epub 2010 Feb 18.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1265-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945625PMC
November 2010

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

J Thorac Oncol 2010 Oct;5(10):1623-9

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181ec1531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020424PMC
October 2010

A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.

Cancer Chemother Pharmacol 2010 Apr 12;65(5):833-8. Epub 2009 Aug 12.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-009-1088-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711187PMC
April 2010

Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.

Cancer 2010 Feb;116(3):670-5

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.24813
Publisher Site
http://dx.doi.org/10.1002/cncr.24813DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815173PMC
February 2010

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.

AJR Am J Roentgenol 2010 Jan;194(1):266-9

Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Howard 118, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.ajronline.org/doi/10.2214/AJR.09.2858
Publisher Site
http://dx.doi.org/10.2214/AJR.09.2858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3676673PMC
January 2010

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Cancer 2007 Aug;110(3):599-605

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22816DOI Listing
August 2007

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.

J Thorac Oncol 2007 Jul;2(7):638-44

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318074bbd0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715043PMC
July 2007

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2007 Mar 1;59(4):467-75. Epub 2006 Aug 1.

Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0286-6DOI Listing
March 2007

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Lung Cancer 2007 Feb 7;55(2):181-5. Epub 2006 Nov 7.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.10.002DOI Listing
February 2007

Lung cancer: computerized quantification of tumor response--initial results.

Radiology 2006 Dec;241(3):892-8

Department of Medical Physics and Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://pubs.rsna.org/doi/10.1148/radiol.2413051887
Publisher Site
http://dx.doi.org/10.1148/radiol.2413051887DOI Listing
December 2006

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.

Cancer 2006 Sep;107(5):1034-41

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.22088
Publisher Site
http://dx.doi.org/10.1002/cncr.22088DOI Listing
September 2006

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.

Cancer Chemother Pharmacol 2006 May 31;57(5):671-7. Epub 2005 Aug 31.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0080-xDOI Listing
May 2006

A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.

Cancer 2002 Oct;95(8):1714-9

Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.10843
Publisher Site
http://dx.doi.org/10.1002/cncr.10843DOI Listing
October 2002

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer.

J Clin Oncol 2002 Aug;20(16):3522-32

Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.02.090DOI Listing
August 2002